Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Galcanezumab, a Monoclonal Antibody to Calcitonin Gene-Related Peptide, in Healthy Japanese and Caucasian Subjects

s : American Headache Society® 58th Annual Scientific Meeting. Headache. 2016; 56(Suppl 1) : PS29. doi : 10.1111/head. 12832. 17) Bourdage JS, Cook CA, Farrington DL, Chain JS, Konrad RJ. An Affinity Capture Elution (ACE) assay for detection of anti-drug antibody to monoclonal antibody therapeutics in the presence of high levels of drug. J Immunol Methods. 2007; 327 (1-2) : 10-17. doi : 10.1016/j.jim.2007.07.004. 18) de Hoon J, Monteith D, Vermeersch S, Van Hecken A, Abu-Raddad E, Collins E, et al. Safety, pharmacokinetics, and pharmacodynamics of LY2951742: a monoclonal antibody targeting CGRP. In : International Headache Congress 2013 Program of Abstracts. Cephalalgia. 2013; 33 (Suppl 8) : P367. doi : 10.1177/0333102413490487. 19) Miller B, Collins EC, Hodsdon M, Camporeale A, Nguyen H, Oakes T, et al. Evaluation of treatment-emergent anti-drug antibodies following administration of LY2951742, a calcitonin gene-related peptide antibody, to migraine patients. In : Program Abstracts : American Headache Society®58th Annual Scientific Meeting. Headache. 2016; 56(Suppl 1) : PS43. doi : 10.1111/head.12832. 20) Davda JP, Hansen RJ. Properties of a general PK/PD model of antibody-ligand interactions for therapeutic antibodies that bind to soluble endogenous targets. MAbs. 2010; 2 (5) : 576-88. doi : 10.4161/mabs.2.5.12833. NAKANO, et al. : Safety and PK of Galcanezumab in Japanese Subjects 139